A Randomized Phase 1 Study Evaluating Pharmacokinetics, Safety, and Tolerability of a High‐Concentration, Long‐Acting Cabotegravir Formulation in Adults Without HIV
Sign Up to like & getrecommendations! Published in 2025 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1538
Abstract: Long‐acting (LA) cabotegravir 200‐mg/mL (CAB200) injections are approved for HIV‐1 prevention and as a complete LA HIV‐1 treatment regimen with rilpivirine. A high‐concentration suspension formulation, cabotegravir 400 mg/mL (CAB400‐D), was developed to enable less frequent… read more here.
Keywords: long acting; hiv; cab400; cabotegravir ... See more keywords